Weibin Wu

Dr. Weibin Wu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YHYun Huang
Yun Huang
SGShan Guo
Shan Guo
YLYing Lin
Ying Lin
LHLiyun Huo
Liyun Huo
HYHongmei Yan
Hongmei Yan
TTTianyu Tao
Tianyu Tao
Metastasis, a major cause of cancer-related mortality worldwide, frequently occurs early in the diagnosis of lung adenocarcinoma (LUAD). However, the precise molecular mechanisms governing the aggressive metastatic behavior of LUAD remain incompletely understood. In this study, we present compelling evidence indicating that the long noncoding RNA linc01703 is significantly downregulated in metastatic lung cancer cells. Intriguingly, in vivo experiments revealed that Linc01703 exerted a profound inhibitory effect on lung cancer metastasis without discernible impact on the in vitro proliferation or invasion capacities of LUAD cells. Mechanistically, Linc01703 enhanced the interaction between Rab27a, SYTL1, and CD81, consequently promoting the secretion of CD81+ exosomes. These exosomes, in turn, suppressed the infiltration of immune cells within the tumor microenvironment, thereby impeding LUAD metastasis. Importantly, our analysis of lung cancer tissues revealed a correlation between reduced CD81 expression and an unfavorable patient prognosis. Collectively, our findings suggest that Linc01703 functions as a metastasis suppressor by facilitating the secretion of CD81+ exosomes through the formation of the Rab27a/SYTL1/CD81 complex.

6 March 2026 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
TTTianyu Tao
Tianyu Tao
XFXianming Feng
Xianming Feng
YYYi Yang
Yi Yang
BLBangdong Liu
Bangdong Liu
JLJiaer Liang
Jiaer Liang
MLMengfeng Li
Mengfeng Li

14 August 2025 in JMIR Medical Informatics
Verified
Journal Article
Open access
YHYuanheng Huang
Yuanheng Huang
GYGuozhen Yang
Guozhen Yang
YSYahui Shen
Yahui Shen
HCHuiguo Chen
Huiguo Chen
WWWeibin Wu
Weibin Wu
JZJian Zhang
Jian Zhang
Background: Large language models (LLMs) have made significant advancements in natural language processing (NLP) and are gradually showing potential for application in the medical field. However, LLMs still face challenges in medicine. Objective: This study aims to evaluate the efficiency, accuracy, and cost of LLMs in handling complex medical cases and to assess their potential and applicability as tools for clinical decision support. Methods: We selected cases from the database of the Department of Cardiothoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University (2021‐2024), and conducted a multidimensional preliminary evaluation of the latest LLMs in clinical decision-making for complex cases. The evaluation included measuring the time taken for the LLMs to generate decision recommendations, Likert scores, and calculating decision costs to assess the execution efficiency, accuracy, and cost-effectiveness of the models. Results: A total of 80 complex cases were included in this study, and the performance of multiple LLMs in clinical decision-making was evaluated. Experts required 33.60 minutes on average (95% CI 32.57‐34.63), far longer than any LLM. GPTo1 (0.71, 95% CI 0.67‐0.74), GPT4o (0.88, 95% CI 0.83‐0.92), and Deepseek (0.94, 95% CI 0.90‐0.96) all finished under a minute without statistical differences. Although Kimi, Gemini, LLaMa3-8B, and LLaMa3-70B took 1.02‐3.20 minutes, they were still faster than experts. In terms of decision accuracy, Deepseek-R1 had the highest accuracy (mean Likert score=4.19), with no significant difference compared to GPTo1 (P=.699), and both performed significantly better than GPT4o, Kimi, Gemini, LLaMa3-70B, and LLaMa3-8B (P<.001). Deepseek-R1 and GPTo1 demonstrated the lowest hallucination rates—6/80 (8%) and 5/80 (6%), respectively—significantly outperforming GPT-4o (7/80, 9%), Kimi (10/80, 12%), and the Gemini and LLaMa3 models, which exhibited substantially higher rates ranging from 13/80 (16%) to 25/80 (31%). Regarding decision costs, all LLMs showed significantly lower costs than the Multidisciplinary Team, with open-source models such as Deepseek-R1 offering a zero direct cost advantage. Conclusions: GPTo1 and Deepseek-R1 show strong clinical potential, boosting efficiency, maintaining accuracy, and reducing costs. GPT4o and Kimi performed moderately, indicating suitability for broader clinical tasks. Further research is needed to validate LLaMa3 series and Gemini in clinical decision.

5 November 2025 in Materials Today Bio
Verified
Journal Article
Open access
LLLibao Liu
Libao Liu
YWYonghui Wu
Yonghui Wu
WWWeibin Wu
Weibin Wu
ZLZining Liu
Zining Liu
BCBolin Chen
Bolin Chen
KZKai Zhang
Kai Zhang
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, with a poor prognosis and high metastasis rate. Metastasis involves complex mechanisms, including chemokine secretion by tumor-associated macrophages (TAMs). Using single-cell RNA sequencing (scRNA-seq), we identified enhanced chemokine secretion by M2-type TAMs in metastatic lesions, with CCL20 emerging as a key target. We designed a CCL20-adsorbing nanosponge by engineering macrophages with high CCR6 expression and extracting their membranes. This nanosponge combines targeting ability and chemokine adsorption capacity, enabling precise treatment of high-CCL20 tumors. Additionally, we encapsulated the Toll-like receptor 7/8 agonist R848 within the CCR6-modified macrophage membrane (CCR6-MM) to polarize M2-type TAMs to the M1 phenotype, reducing CCL20 secretion and transforming the immunosuppressive tumor microenvironment. In vitro and in vivo experiments validated the therapeutic potential of the CCR6-MM and R848 combination, demonstrating biocompatibility, macrophage polarization efficacy, and dual inhibitory effects on tumor growth and metastasis. Our findings highlight the potential of chemokine nanosponges as a novel therapeutic strategy for NSCLC metastasis.

20 February 2025 in Clinical Medicine Insights: Oncology
Verified
Journal Article
Open access
XHXiaoying He
Xiaoying He
WWWeibin Wu
Weibin Wu
YWYan Wang
Yan Wang
JXJingyi Xiao
Jingyi Xiao
JFJuanjuan Feng
Juanjuan Feng
HLHai Li
Hai Li
Background: The clinical impact of heart failure (HF) on postoperative outcomes following video-assisted thoracic surgery (VATS) for lung cancer resection remains controversial. This study aimed to assess patient and hospital characteristics related to the type of surgery, as well as the independent impact of HF on surgical outcomes. Methods: We conducted a retrospective analysis using data from the National Inpatient Sample database. A total of 20 693 patients aged 18 years or older, diagnosed with lung cancer, and undergoing lobectomy or sublobar resection via VATS between 2016 and 2020 were included. Patients were stratified based on the presence of HF. The HF-present cohorts were matched to HF-absent controls using a 1:2 nearest-neighbor propensity score-matching (PSM) analysis. The matched cohorts were then compared across several endpoints, including mortality, length of stay (LOS), hospitalization costs, and postoperative complications. Results: After PSM, the study included 1781 patients who underwent lobectomy and 1157 who underwent sublobar resection, with 594 and 386 patients, respectively, having concurrent HF. In both the lobectomy and sublobar resection groups, patients with HF demonstrated significantly higher in-hospital mortality rates ( P < .001), longer LOS ( P < .001), increased total hospital charges ( P < .001), and a greater risk for overall postoperative complications ( P < .001). Conclusions: Among patients with lung cancer undergoing VATS, the presence of HF is associated with an increased risk of postoperative complications. This finding underscores the necessity for enhanced monitoring and care for patients with HF should be treated during the postoperative recovery phase.

1 October 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
KZKai Zhang
Kai Zhang
LLLibao Liu
Libao Liu
JXJiannan Xu
Jiannan Xu
WWWeibin Wu
Weibin Wu
Background: Lung adenocarcinoma (LUAD), the most prevalent subtype of non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality globally. Despite advances in therapy, treatment resistance and poor prognosis necessitate novel therapeutic targets. Nuclear filament-containing protein 2 (NUF2), a component of the nuclear division cycle 80 (NDC80) complex, is implicated in oncogenesis, but its role and molecular mechanisms in LUAD are poorly understood. The aim of this study is to explore the role of NUF2 in malignant development of LUAD in vivo. Methods: Bioinformatics analysis using Gene Expression Profiling Interactive Analysis (GEPIA) and Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) databases evaluated NUF2/BUB1B (BUB1 mitotic checkpoint serine/threonine kinase B) expression and interactions. Functional assays (cell counting kit-8, colony formation, apoptosis, wound healing, transwell) and molecular techniques (real-time quantitative polymerase chain reaction, Western blot, co-immunoprecipitation) were performed in LUAD cell lines (A549, PC-9, NCI-H1975). The binding of NUF2 and BUB1B was verified by co-immunoprecipitation assay. An in vivo LUAD model was established with nude mice and the mTORC1 (mechanistic target of rapamycin complex 1) pathway was examined by Western blot. Results: NUF2 was significantly upregulated in LUAD tissues and correlated with advanced stage and poor survival (P<0.001). Silencing NUF2 suppressed proliferation, migration, and invasion while promoting apoptosis in A549 cells. Mechanistically, NUF2 directly bound to BUB1B, a mitotic checkpoint kinase, and regulated the mTORC1 pathway. Overexpression of BUB1B rescued the anti-tumor effects of NUF2 knockdown, restoring mTORC1 activity (evidenced by phosphorylation of 4EBP1 and S6). In vivo, NUF2 silencing inhibited tumor growth, which was reversed by BUB1B overexpression (P<0.01). Conclusions: NUF2 drives LUAD progression via BUB1B-mediated mTORC1 activation. Targeting the NUF2/BUB1B axis may offer a promising therapeutic strategy to mitigate LUAD malignancy. These findings provide critical insights into the molecular underpinnings of LUAD and highlight potential pathways for clinical intervention.